Hepatitis B and C virus infection and cholangiocarcinoma: A case-control study in Turkey;Hepatit B ve C virüs enfeksiyonu ve kolanjiokarsinom: Türkiye'de bir vaka-kontrol çalıflması

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

Volumn 22, Issue 3, 2012, Pages 187-191

  Onal, Ibrahim K ^a   Parlak, Erkan ^a   Kekilli, Murat ^a   Kurt, Mevlut ^a   Alioglu, Habibe ^a   Disibeyaz, Selcuk ^a   Sayilir, Abdurrahim ^a   Beyazit, Yavuz ^a   Sasmaz, Nurgul ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Cholangiocarcinoma; Hepatitis B; Hepatitis C

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT STONE; BLOOD ANALYSIS; CANCER PATIENT; CASE CONTROL STUDY; CHOLELITHIASIS; COMMON BILE DUCT STONE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRINKING BEHAVIOR; FEMALE; GALLBLADDER CANCER; HEPATITIS B; HEPATITIS C; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONHUMAN; PREVALENCE; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE; TURKEY (REPUBLIC);

EID: 84867476916     PISSN: 1306133X     EISSN: None     Source Type: Journal    
DOI: 10.4999/uhod.10089     Document Type: Article

References (16)

1. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51: (Suppl VI): vi1-vi9, 2002.
2. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 12: 131-150, 2008.
3. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
4. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery 129: 699-703, 2001.
5. Furlan A, Ferris JV, Hosseinzadeh K, Borhani AA. Gallbladder carcinoma update: multimodality imaging evaluation, staging, and treatment options. AJR Am J Roentgenol 191: 1440-1447, 2008.
6. Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma: An update focusing on risk factors. Cancer Sci 101: 579-585, 2010.
7. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangi-ocarcinoma. HPB 10: 77-82, 2008.
8. Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 25: 933-940, 1996.
9. Tao LY, He XD, Qu Q, et al. Risk factors for intrahepa-tic and extrahepatic cholangiocarcinoma: a case-control study in China. Liver Int 30: 215-221, 2010.
10. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intra- and extrahepatic cholangiocarcinoma in the United States: a population based case-control study. Clin Gastroenterol Hepatol 5: 1221-1228, 2007.
11. Wang WL, London WT, Feitelson MA. Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 51: 4971-4977, 1991.
12. Zou SQ, Qu ZL, Li ZF, Wang X. Hepatitis B virus X gene induces human telomerase reverse transcriptase mRNA expression in cultured normal human cholangi-ocytes. World J Gastroenterol 10: 2259-2262, 2004.
13. Yin F, Chen B. Detection of hepatitis C virus RNA sequences in hepatic portal cholangiocarcinoma tissue by reverse transcription polymerase chain reaction. Chin Med J (Engl) 111: 1068-1070, 1998.
14. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis 5: 191-218, 2001.
15. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128: 620-626, 2005.
16. Kubo S, Kinoshita H, Hirohashi K, Hamba H. Hepato-lithiasis associated with cholangiocarcinoma. World J Surg 19: 637-641, 1995.